NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Nov 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Indications (7)
chronic iron overload in patients 10 years of ageolder with non-transfusion-dependent thalassemia (NTDT) syndromesa liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weighta serum ferritin greater than 300 mcg/Lchronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of ageoldera liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw)
Clinical Trials (5)
Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
Started Jan 2024
400 enrolled
Chronic Iron Overload
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Started Feb 2018
39 enrolled
Myelodysplasia
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Started Jan 2018
44 enrolled
Iron Overload
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Started Jan 2018
45 enrolled
Hereditary Hemochromatosis
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Started Jul 2017
148 enrolled
Transfusion-dependent ThalassemiaNon-transfusion-dependent Thalassemia